AC
Non verificato

ACADIA Pharmaceuticals Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VariePsichiatriaSalute
20/07/2026
Industria
Psichiatria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
1.00
15/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Psichiatria
Sanità
Salute
Farmaceutica
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
1.00
06/07/2026
Psichiatria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
1.00
26/06/2026
Industria
Biotecnologia
Farmaceutica
Salute
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
1.00
06/05/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Sanità
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
1.00
28/04/2026
Eventi
Web e Social Network
Scienza
Biotecnologia
Farmaceutica
Salute
Psichiatria
Medicina - Varie
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
1.00
17/04/2026
Eventi
Fiere
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
1.00
15/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Psichiatria
Sanità
Salute
Farmaceutica
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0